Navigation Links
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
Date:8/13/2009

BOTHELL, WA and VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer. This trial is separate from an ongoing Phase 1 trial of OGX-427 administered systemically in patients with various solid tumors. OGX-427 is a second-generation antisense drug that is designed to reduce production of Heat Shock Protein 27 (Hsp27), a cell-survival protein that inhibits apoptotic cell death through multiple pathways.

The study, which will enroll up to 36 patients with bladder cancer, is designed to determine the safety and potential benefit of OGX-427 administered directly into the bladder using a catheter, which is called intravesical instillation. In addition, the study will measure the direct effect of OGX-427 on expression of Hsp27 in bladder tumor cells as well as determine the pharmacokinetics and pharmacodynamics of OGX-427 when delivered by intravesical instillation. The study is sponsored by the National Cancer Institute of Canada (NCIC). Dr. Alan So, an Assistant Professor in the Department of Urologic Sciences at the University of British Columbia and Research Scientist at the Vancouver Prostate Centre, is the study's principal investigator.

"The current treatment for superficial bladder cancer is local resection with immunotherapy, which often has significant local and systemic side effects," said Dr. So. "Because of the limitations of current adjuvant options, a treatment option like intravesical delivery of OGX-427 that is specifically targeted to the tumor would be desirable."

"This Phase 1 trial of OGX-427 is an attractive trial design as removal of bladder tumor
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Bronstein, Gewirtz & Grossman, ... of the securities of PDL BioPharma, Inc. ("PDL BioPharma" ... Such investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. ... of its executives violated federal securities laws. ...
(Date:9/17/2014)... September 17, 2014 ... has shown positive data in a Phase 2a proof ... , Glenmark Pharmaceuticals today announced ... 1 (TRPA1) antagonist, GRC 17536 has shown positive data ... proof of concept study conducted on 138 patients in ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... New study finds patients who opt for surgery have decreased pain, ... with the spine disease called degenerative spondylolisthesis * ... pain over time compared to those who do not have surgery, ... The Journal of Bone and Joint Surgery ...
... GAITHERSBURG, Md., June 1 Overall survival data in ... GenVec,s ongoing Phase III Pancreatic Cancer Clinical Trial with ... Society of Clinical Oncology Annual Meeting in Orlando, FL. ... ) , , The poster ...
Cached Medicine Technology:Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4TNFerade(TM) Phase III Data Presented at ASCO 2TNFerade(TM) Phase III Data Presented at ASCO 3
(Date:9/17/2014)... Leading eco-friendly beauty brand , Lotus ... new vegan and gluten-free Sugar Cane Fruit Mask. Their ... results skincare testers were looking for. , “My ... mask that provided results, and I think I accomplished ... Fruit Mask combines Willow bark (Salix Alba extract), a ...
(Date:9/17/2014)... (HealthDay News) -- Scientists have developed a blood-cleansing device, ... the way the blood infection sepsis is treated. ... said their device works outside the body like a ... toxins out of patients, blood. "Even with the ... care units at least 30 percent of the time," ...
(Date:9/17/2014)... to reduce the need for invasive biopsies in patients ... , In a new study, researchers developed a math ... kidney inflammation to interstitial fibrosis, scarring in the ... is the only existing way to reach a definitive ... model could also be used to monitor the effectiveness ...
(Date:9/17/2014)... 17, 2014 CarePoint Health became the ... 150 CarePoint Health employees participated in the Ice Bucket ... Association. The event took place on September 9, ... CarePoint Health donated $100 to the ALS Association for ... total of approximately $15,000. The Ice Bucket Challenge was ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 ... made good on their pledge to cut calories in their ... together through the Healthy Weight Commitment Foundation, pledged to remove ... and 1.5 trillion by 2015. They,ve actually reduced far more: ... pledge and exceeded their pledge," said lead researcher Shu Wen ...
Breaking Medicine News(10 mins):Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:'Biospleen' Suggests New Way to Treat Blood Infection 2Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 3Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... Minimal or Free and Best Option for Prevention;,Yet 5% Would ... Staying,Healthy., YONKERS, N.Y., Nov. 11 According to a ... to get the,flu vaccine this year, despite its being the ... long list of poor excuses,for not getting the vaccine, including ...
... First Large Scale Study Finds 73% Are From ... Consumers Union,called on hospitals today to take ... (C.-diff.) infections in light of a new report,showing ... estimates had,indicated. As the rate of hospital acquired ...
... French . , Montreal, November 11, 2008 ... that,s enabled them to reproduce complex cellular environments and ... a new study published in the journal Lab on ... Hospital Research Centre, McGill University and the Montreal Neurological ...
... is playing a key role in the largest, most ... Mental Health (NIMH) of adolescents and young adults at ... study joins the resources of Emory and seven other ... precise predictors for psychosis, and a better understanding of ...
... be an independent cause of excessive daytime sleepiness ... Researchers from Sweden performed polysomnography testing on 400 ... The apnea-hypopnea index (AHI) was calculated, and women ... very often were considered habitual snorers. Habitual snoring ...
... Proton Pump Inhibitors increase risk of major cardiovascular event by more ... for patients taking Plavix(R) Study may anticipate a role for genetic testing ... ... MHS ) today presented a study at the 2008 Scientific,Sessions of the ...
Cached Medicine News:Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 3Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 4Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 2Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 3Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 4Health News:New laser method reproduces art masterworks to protein patterns 2Health News:Pivotal Emory study focuses on teens at risk for psychosis 2Health News:Pivotal Emory study focuses on teens at risk for psychosis 3Health News:Journal CHEST: Nov. highlights 2Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 2Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 3Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 4
... Pulse Oximeter monitors SpO2, pulse ... is designed to provide fast, ... The device rejects spontaneous motion ... operator of excess artifacts and ...
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
Halogen-free immersion oil based on ester oil....
Immersion Oil, 150 cs...
Medicine Products: